467 related articles for article (PubMed ID: 27033631)
1. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.
Martirosov DM; Lodise TP
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):266-75. PubMed ID: 27033631
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
[TBL] [Abstract][Full Text] [Related]
4. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.
Temkin E; Adler A; Lerner A; Carmeli Y
Ann N Y Acad Sci; 2014 Sep; 1323():22-42. PubMed ID: 25195939
[TBL] [Abstract][Full Text] [Related]
6. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.
van Duin D; Kaye KS; Neuner EA; Bonomo RA
Diagn Microbiol Infect Dis; 2013 Feb; 75(2):115-20. PubMed ID: 23290507
[TBL] [Abstract][Full Text] [Related]
8. Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?
Metan G; Akova M
Curr Opin Infect Dis; 2016 Dec; 29(6):555-560. PubMed ID: 27584588
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
[TBL] [Abstract][Full Text] [Related]
10. The rapid spread of carbapenem-resistant Enterobacteriaceae.
Potter RF; D'Souza AW; Dantas G
Drug Resist Updat; 2016 Nov; 29():30-46. PubMed ID: 27912842
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.
Nabarro LE; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2015 Dec; 34(12):2307-11. PubMed ID: 26363636
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).
Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2015 Oct; 83(2):183-6. PubMed ID: 26164275
[TBL] [Abstract][Full Text] [Related]
13. Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: what is in the pipeline?
Horcajada JP; Torre-Cisneros J; Peña C; Fariñas MC
Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():56-60. PubMed ID: 25542053
[TBL] [Abstract][Full Text] [Related]
14. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections.
Huang SR; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2014 Jun; 47(3):187-96. PubMed ID: 23200553
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-resistant Enterobacteriaceae: a potential threat.
Schwaber MJ; Carmeli Y
JAMA; 2008 Dec; 300(24):2911-3. PubMed ID: 19109119
[No Abstract] [Full Text] [Related]
16. The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology.
El-Herte RI; Kanj SS; Matar GM; Araj GF
J Infect Public Health; 2012 Jun; 5(3):233-43. PubMed ID: 22632597
[TBL] [Abstract][Full Text] [Related]
17. The management of multidrug-resistant Enterobacteriaceae.
Bassetti M; Peghin M; Pecori D
Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.
Tumbarello M; Losito AR; Giamarellou H
Curr Opin Infect Dis; 2018 Dec; 31(6):566-577. PubMed ID: 30379732
[TBL] [Abstract][Full Text] [Related]
19. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
20. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
